NTLX Neurothera Labs Inc.
Neurothera Labs Inc. engages in the development of a portfolio of drugs based on cannabinoid molecules. The company develops programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder, and status epilepticus. It also focuses on e-commerce operations, which sells hemp-based products. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Newark, Delaware. Neurothera Labs Inc. is a subsidiary of SciSparc Ltd.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Neurothera Labs (CVE: NTLX)
›
Neurothera Labs (CVE: NTLX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.
The shares were at 4.000 CAD on 18 November 2026, up 90.5% over 52 weeks. Its 52-week range is 1.610 CAD to 5.320 CAD: the price is 24.8% below the high and 148.4% above the low.
Its market capitalisation is 339.60M CAD.
Neurothera Labs reports revenue down 38.2% year over year.
Its debt exceeds its cash by 7.00K USD, a debt-to-equity ratio of 6.97. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 28 January 2027.